Page 3 - Sequenom Inc News Today

Dublin, June 29, 2022 (GLOBE NEWSWIRE) -- The "Carrier Screening Market Share, Size, Trends, Industry Analysis Report, By Type; By Medical Condition; By...

/PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled...

On May 23rd, U.S. District Court Judge James V. Selna of the Central District of California granted summary judgement to Defendant Sweegen, Inc. on its motion that Plaintiff Pure Circle...

The faintest glimmer of hope crept over the clouded patent law horizon today, when the Solicitor General provided the government's views to the Supreme Court in an amicus brief in...

San Diego, CA (PRWEB) May 04, 2022 -- Juno Diagnostics™, Inc. (JunoDx™), a women’s health company focused on improving equitable access to prenatal care led

Dublin, March 17, 2022 (GLOBE NEWSWIRE) -- The "Non-invasive Prenatal Testing Global Market Report 2022, By Type, By End User, By Instruments, By...

* Not for trading, but in connection with the registration of American Depositary Shares, pursuant to the requirements of the Securities and Exchange Commission. Securities registered or to be registered pursuant to Section 12(g) of the Act: None None Indicate the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered by the annual report: Title of each class Ordinary Shares, nominal...

EXECUTIVE CHANGES: New CFOs for Sensyne, Focusrite, Bango, 4D Pharma Mon, 1st Mar 2021 16:41 (Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Monday and not separately reported by Alliance News: Sensyne Health PLC - Oxford, England-based clinical technology using artificial intelligence - Moves Chief Investment Officer Richard Pye to chief financial officer and executive director, while interim CFO Michael Norris moves to non-execu...

Insilico Medicine discovers novel preclinical candidate to address idiopathic pulmonary fibrosis Insilico Medicine has demonstrated a breakthrough in Artificial Intelligence ("AI") and drug discovery -- linking together generative chemistry and biology for the first time -- to discover a novel preclinical candidate addressing idiopathic pulmonary fibrosis ("IPF") and be validated with multiple human cell and animal model experiments. Often found implicated in a wide range of diseases and multip...

Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI Insilico Medicine Achieves Industry First Nominating Preclinical Candidate for Idiopathic Pulmonary Fibrosis With Both Novel Drug Target and Novel Molecule Discovered by Artificial Intelligence HONG KONG, Feb. 24, 2021 /PRNewswire/ -- Insilico Medicine has demonstrated a breakthrough in Artificial Intelligence ("AI") and drug discovery - linking together generative chemistry and biology for the first tim...